Roche Pharma AG
PolandAll drugs from this manufacturer
-
The medicinal product is used in the treatment of Parkinson's disease. Some of its forms are also indicated for the symptomatic treatment of restless legs syndrome (RLS), including in patients suffering from this syndrome in connection with renal failure requiring dialysis therapy.
Dosage form: capsules
Active substance Dosage levodopa 200 mg benserazide 50 mg ATC: N04BA02
-
Madopar is used in the treatment of Parkinson's disease. Some of its formulations are also indicated for the symptomatic treatment of restless legs syndrome (RLS), including in patients suffering from this syndrome in connection with renal failure requiring dialysis therapy.
Dosage form: capsules
Active substance Dosage levodopa 100 mg benserazide 25 mg ATC: N04BA02
-
The medicinal product is used in the treatment of Parkinson's disease and for the symptomatic treatment of restless legs syndrome (RLS), in this case in patients suffering from this syndrome in connection with renal failure requiring dialysis therapy.
Dosage form: suspension, oral, for preparation from tablets
Active substance Dosage levodopa 100 mg benserazide 25 mg ATC: N04BA02
-
Madopar is used in the treatment of Parkinson's disease. Some of its formulations are also indicated for the symptomatic treatment of restless legs syndrome (RLS), including in patients suffering from this syndrome in connection with renal failure requiring dialysis therapy.
Dosage form: capsules
Active substance Dosage levodopa 50 mg benserazide hydrochloride 12.5 mg ATC: N04BA02
-
The medicinal product is used in the treatment of Parkinson's disease and in the symptomatic treatment of restless legs syndrome (RLS), in this case in patients with renal failure requiring dialysis therapy.
Dosage form: suspension, oral, for preparation from tablets
Active substance Dosage levodopa 50 mg benserazide 12.5 mg ATC: N04BA02
-
Madopar is used in the treatment of Parkinson's disease and in the symptomatic treatment of restless legs syndrome (RLS), including in patients with renal failure requiring dialysis therapy.
Dosage form: capsules
Active substance Dosage levodopa 100 mg benserazide hydrochloride 28.5 mg ATC: N04BA02
-
It is a solution for nebulizer inhalation containing dornase alfa.
Dosage form: solution for inhalation
Active substance Dosage dornase alfa 2.5 mg ATC: R05CB13